What is Circio Holding ASA's (CRNA.OL) StockRank?

MoatMap's StockRank for Circio Holding ASA (CRNA.OL) is 20/100, with a Sell signal. This is a composite score combining Quality (17), Value (25), and Momentum (65) factor ranks across MoatMap's 20,000+ stock universe.

Does Circio Holding ASA have an economic moat?

Circio Holding ASA (CRNA.OL) has a Quality factor score of 17/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Circio Holding ASA a buy, hold, or sell?

MoatMap's current signal for Circio Holding ASA (CRNA.OL) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Circio Holding ASA in?

Circio Holding ASA (CRNA.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CRNA.OL

SELLREMOVE

Circio Holding ASA · Healthcare · Norway · $232M · Avg Vol: $7M/d

StockRank

P/E (TTM)

—

ROE

—

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Circio Holding is a micro-cap Norwegian biotechnology firm. It is a pre-revenue, highly speculative business that does not meet any of our quality, moat, or cash-flow requirements.

COMPANY DESCRIPTION

Circio Holding ASA is a clinical-stage biotechnology company developing next-generation circular RNA (circRNA) medicines and cancer immunotherapies. The company's proprietary circRNA platform aims to deliver sustained therapeutic protein expression in vivo, overcoming the limitations of traditional mRNA. Its competitive moat is secured by a robust patent portfolio, specialized scientific expertise, and strategic collaborations in the emerging field of RNA therapeutics.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	1.0M	12,695	0	0	-98.8%
EPS	-0.17	-0.05	0.07	-0.04	—
Shares	274.3M	274.3M	274.3M	148.5M	-45.9%
Debt	6.5M	11.4M	1.8M	0.9M	-49.1%
Equity	0.3M	-10.2M	-1.3M	-1.3M	—
Op CF	-11.2M	-9.2M	-4.2M	-4.7M	—
Inv CF	-0.5M	0.3M	-19,507	0	—
Fin CF	-0.4M	4.3M	3.8M	3.5M	—

PRICE (1Y)-14.1%

SMA 50SMA 200

$0.84

RSI (14)

46.3

52W High

$1.49

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC (ROA)

-157.5%*2.9

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%40.3

FCF/Assets

-257.6%0.3

Piotroski

212.0

Int. Cover

-50.0x6.0

D/E Ratio

—N/A

Current Ratio

0.46x1.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-42.8x25.0

P/FCF

—N/A

P/B

-93.4x25.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

57%25.1

RS 6M

468%99.9

SMA 50/200

2.43x100.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—72.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$232M

P/E (Forward)

—

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRNA.OL are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CRNA.OL	Circio Holding ASA(you)	$232M	20	SELL
TRMED.OL	Thor Medical ASA	$157M	20	SELL
ZLNA.OL	Zelluna ASA	$51M	20	SELL
AZT.OL	ArcticZymes Technologies ASA	$107M	45	HOLD
NYKD.OL	Nykode Therapeutics AS	$109M	46	HOLD
PHO.OL	Photocure ASA	$166M	70	BUY
MEDI.OL	Medistim ASA	$438M	86	STRONG BUY
VISTN.OL	Vistin Pharma ASA	$93M	99	STRONG BUY

Peer medians: ROE 10.1% · P/E 23.0x · Gross margin 94.4%

Circio Holding ASA (CRNA.OL) — Stock Score Summary

Circio Holding ASA (CRNA.OL) has a MoatMap StockRank of 20/100 based on Quality (17/100), Value (25/100), and Momentum (65/100) factor scores. The current signal is SELL. Circio Holding is a micro-cap Norwegian biotechnology firm. It is a pre-revenue, highly speculative business that does not meet any of our quality, moat, or cash-flow requirements.

Key Financial Metrics

Price	$0.84
Market Cap	$232M
Price/Book	-93.45
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-310K

Circio Holding ASA operates in the Biotechnology industry, part of the Healthcare sector (Norway).

Frequently Asked Questions

What is Circio Holding ASA’s (CRNA.OL) StockRank?: MoatMap’s StockRank for Circio Holding ASA (CRNA.OL) is 20/100, with a Sell signal. It is a composite of Quality (17), Value (25), and Momentum (65) factor ranks across MoatMap’s 20,000+ stock universe.
Does Circio Holding ASA have an economic moat?: Circio Holding ASA (CRNA.OL) has a Quality factor score of 17/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Circio Holding ASA a buy, hold, or sell?: MoatMap’s current signal for Circio Holding ASA (CRNA.OL) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Circio Holding ASA in?: Circio Holding ASA (CRNA.OL) operates in the Healthcare sector, specifically the Biotechnology industry (Norway).